Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Background In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole
resulted in significantly longer progression-free survival than letrozole alone among …

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced
breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine …

Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

Background: Ribociclib has demonstrated a statistically significant overall survival benefit in
pre-and postmenopausal patients with hormone receptor positive/human epidermal growth …

Anti-estrogen therapy is a key component of the treatment of both early and advanced-stage
hormone receptor (HR)-positive breast cancer. This review discusses the recent emergence …

Purpose: To conduct an updated exploratory analysis of overall survival (OS) with a longer
median follow-up of 73.3 months and evaluate the prognostic value of molecular analysis by …

Breast cancer is the second leading cause of death for women worldwide. While
monotherapy (single agent) treatments have been used for many years, they are not always …

Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …